Bio-Techne has outperformed the broader market over the past year, but analysts are cautious about the stock’s prospects.
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
3 High-Flying Stocks We Approach with Caution
MINNEAPOLIS , Aug. 13, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is issuing a correction to its dividend announcement released yesterday. The initial version incorrectly stated...
Bio-Techne (NASDAQ:TECH) Surprises With Q2 CY2026 Sales
MINNEAPOLIS , Aug. 12, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2026.
MINNEAPOLIS , Aug. 12, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June...
Barchart Research What to Expect from TECH Earnings TECH Generated August 11, 2026 Current Price $72.15 EPS Estimate $$0.46 Consensus Rating Hold Average Move 7.01% Bio-Techne's Recovery Timeline Hinges...
Barchart Research What to Expect from TECH Earnings TECH Generated August 4, 2026 Current Price $72.09 EPS Estimate $$0.46 Consensus Rating Hold Average Move 7.01% Bio-Techne: Six Quarters of Pharma Strength...